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Background
Activation of the nitric oxide – soluble guanylate cyclase –
cyclic guanosine monophosphate (NO-sGC-cGMP) path-
way can induce potent cardioprotection-like effects
against ischemia-reperfusion injury. We investigated the
effects of pharmacological preconditioning with cinaci-
guat (BAY 58-2667), a novel sGC-activator on myocardial
and coronary vascular function during reperfusion in a
canine model of cardioplegic arrest and extracorporal cir-
culation.
Materials and methods
Vehicle- (control group, n = 6) and cinaciguat-pretreated
(8.33 μg/h iv. for 30 min; n = 7 low-dose treatment group
and 25 μg/h iv. for 30 min; n = 6 high-dose treatment
group) anesthetized dogs underwent cardiopulmonary
bypass with 60 min of hypothermic cardiac arrest. Left
and right ventricular end-systolic pressure volume rela-
tionship (ESPVR) was measured by a combined pressure-
volume conductance catheter at baseline and after 60 min
of reperfusion. Left anterior descending coronary blood
flow, vasodilatation to acetylcholine and myocardial level
of adenosine triphosphate were determined.
Results
Compared to control, pharmacological preconditioning
with cinaciguat (25 μg/h) led to significantly higher myo-
cardial adenosine triphosphate content, to a better recov-
ery of left and right ventricular contractility (Δ slope of left
ventricular ESPVR given as percent of baseline: 102.4 ±
19.1 vs. 56.0 ± 7.1%, p < 0.05) and to a higher coronary
blood flow (49.6 ± 3.5 vs. 28.0 ± 3.9 ml/min, p < 0.05).
Endothelium-dependent vasodilatory responses to acetyl-
choline were improved in the treatment groups.
Conclusion
Preconditioning with cinaciguat improves myocardial
and endothelial function after cardiopulmonary bypass
with hypothermic cardiac arrest. The observed protective
effects imply that pharmacological sGC-activation could
be a novel therapeutic option in the protection against
ischemia-reperfusion injury in cardiac surgery.
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